Latest NTEP Guidelines for Tuberculosis Treatment
Drug-Susceptible Tuberculosis
The National Tuberculosis Elimination Program (NTEP) has transitioned to a daily fixed-dose combination (FDC) regimen, replacing the previous thrice-weekly DOTS approach. 1, 2
Standard 6-Month Regimen
- Adults and children with drug-susceptible pulmonary TB receive 2 months of HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol) followed by 4 months of HR, administered as daily FDC tablets without mandatory directly observed therapy. 1, 2
- For disseminated or miliary TB without CNS involvement, extend the continuation phase to 7 months (total 9 months). 3
- CNS tuberculosis (tuberculous meningitis) requires a minimum of 12 months of treatment with rifampin, isoniazid, pyrazinamide plus a fourth drug (streptomycin, ethambutol, or ethionamide) for the first 2 months, plus corticosteroids (prednisone ≈60 mg/day tapered over weeks). 3
Alternative 4-Month Regimen
- WHO conditionally recommends a 4-month regimen of rifapentine, isoniazid, pyrazinamide, and moxifloxacin for adults ≥12 years with pulmonary drug-susceptible TB, shortening therapy from the traditional 6 months. 1, 4
- Children with non-severe drug-susceptible TB may receive a 4-month regimen using weight-adjusted standard first-line drugs (based on SHINE trial data). 1, 4
Critical Implementation Note
- Despite daily dosing, adherence is problematic: objective urine drug metabolite testing reveals only 53.4% adherence versus 63.7% self-reported adherence, indicating that patient-reported adherence is unreliable. 5
- Suboptimal plasma concentrations of rifampicin occur in 60% of patients and isoniazid in 25% of patients on daily FDC regimens, though favorable outcomes are still achieved, likely due to adequate pyrazinamide levels. 2
Isoniazid-Resistant, Rifampicin-Susceptible TB
Treat with 6 months of rifampin, ethambutol, pyrazinamide, plus a fluoroquinolone (levofloxacin or moxifloxacin)—do NOT add injectable agents (streptomycin, amikacin), as they provide no benefit and increase toxicity. 1
- High-dose isoniazid may be added when the resistance mutation is inhA (lower-level resistance), though evidence is limited. 1
- If fluoroquinolone resistance or contraindication exists, use rifampin, ethambutol, and pyrazinamide for 6 months. 1
Multidrug-Resistant/Rifampicin-Resistant TB (MDR/RR-TB)
Diagnostic Approach
- CBNAAT (GeneXpert) is the WHO-recommended first-line test for all suspected TB cases; it simultaneously detects Mycobacterium tuberculosis and rifampicin resistance. 6, 1
- Standard CBNAAT does not detect isoniazid resistance—line-probe assay or culture-based DST is required. 6, 1
- Comprehensive DST for fluoroquinolones and all second-line drugs is mandatory to guide regimen selection; fluoroquinolone DST is pivotal for choosing between BPaLM, BPaL, the 9-month regimen, or longer individualized therapy. 6, 1
Baseline Evaluation Before MDR/RR-TB Therapy
- Obtain CBC, liver and renal function tests, ECG, weight, HIV status, pregnancy test, detailed history of prior TB drug exposure, electrolytes (K⁺, Mg²⁺, Ca²⁺) for QTc-prolongation risk, visual-acuity testing, and audiometry if injectable agents might be used. 6, 1
Regimen Hierarchy (Most to Least Preferred)
1. BPaLM Regimen (6 Months) – First-Line Option
BPaLM (bedaquiline + pretomanid + linezolid + moxifloxacin) is the preferred first-line treatment for eligible MDR/RR-TB patients. 6, 1
- Eligibility: age ≥14 years, no fluoroquinolone resistance, no resistance to bedaquiline/pretomanid/linezolid; extensive pulmonary disease and cavitation are no longer contraindications (2023 WHO update); HIV co-infection does not preclude use. 6, 1
- Absolute contraindications: pregnancy or breastfeeding (pretomanid reproductive toxicity unknown); CNS, osteoarticular, or miliary TB (require longer therapy); confirmed resistance to any BPaLM component. 6, 3, 1
- Dosing:
- If fluoroquinolone resistance is detected after starting BPaLM, stop moxifloxacin and continue as BPaL (without moxifloxacin) for a total of 9 months. 6, 1
2. BPaL Regimen (6–9 Months) – For Pre-XDR TB
BPaL (bedaquiline + pretomanid + linezolid, without moxifloxacin) is indicated for MDR-TB with fluoroquinolone resistance (pre-XDR). 6, 1
- Duration: 6 months, extendable to 9 months if sputum cultures remain positive between months 4–6. 6, 1
- Eligibility and monitoring are identical to BPaLM except fluoroquinolone resistance is expected. 6, 1
3. 9-Month All-Oral Regimen – When BPaLM/BPaL Not Feasible
Use when BPaLM/BPaL cannot be administered due to contraindications, intolerance, or drug unavailability; patient must be fluoroquinolone-susceptible with ≤1 month prior second-line drug exposure. 6, 1
- Intensive phase (4–6 months): bedaquiline + linezolid (or ethionamide) + fluoroquinolone (levofloxacin/moxifloxacin) + clofazimine + pyrazinamide + ethambutol + high-dose isoniazid (if applicable). 6, 1
- Continuation phase (≈5 months): fluoroquinolone + clofazimine + pyrazinamide + ethambutol. 6, 1
- Exclusions: severe extrapulmonary TB (CNS, miliary, osteoarticular) requires the longer 18–20-month regimen; pregnancy contraindicates ethionamide—replace with a linezolid-based variation. 6, 3, 1
- Do NOT extend the intensive phase beyond 6 months, even with delayed culture conversion. 6, 3
4. Individualized 18–20-Month Regimen – Last Resort
Use only when all other regimens are unsuitable due to extensive resistance, intolerance, drug-drug interactions, or contraindicated disease sites. 6, 1
- Core drug grouping (WHO):
- Group A (use all three if possible): fluoroquinolone (levofloxacin/moxifloxacin), bedaquiline, linezolid—strong recommendations. 6, 1
- Group B (add at least one): clofazimine, cycloserine/terizidone—conditional. 6, 1
- Group C (add as needed to reach ≥4 effective drugs): ethambutol, delamanid (≥3 years), pyrazinamide, carbapenems + amoxicillin-clavulanate, amikacin (only if no oral alternatives). 6, 1
- Core requirements: ≥4 effective drugs in the intensive phase (5–7 months after culture conversion) and ≥3 in the continuation phase; total duration 18–20 months (15–21 months after conversion). 6, 1
- Kanamycin and capreomycin are strongly discouraged due to poor outcomes and high toxicity. 6, 1
- Do NOT add a single drug to a failing regimen; at least two susceptible drugs must be introduced together to prevent functional monotherapy and resistance amplification. 6, 1
Monitoring During Treatment
Drug-Susceptible TB
- Obtain sputum cultures monthly until two consecutive negatives are reported; sputum conversion is expected by 3 months. 3
- Persistent smear-positivity at 3 months warrants evaluation for non-adherence, failure, or resistance. 3
MDR/RR-TB
- ECG monitoring: baseline, weeks 2,4,8,12, then monthly to detect QTc prolongation from bedaquiline, moxifloxacin, and clofazimine; stop bedaquiline if QTcF >500 ms. 6, 1
- Hematologic monitoring: monthly CBC to identify linezolid-induced myelosuppression; if toxicity occurs, reduce linezolid dose to 300 mg daily. 6, 1
- Neurologic monitoring: monthly assessment for peripheral neuropathy (linezolid) and optic neuropathy (linezolid, ethambutol). 6, 1
- Liver function tests monthly: stop bedaquiline if ALT/AST >8× ULN or ALT/AST >3× ULN + bilirubin >2× ULN. 1
- Active drug-safety monitoring (aDSM) is mandatory for all DR-TB patients. 6, 1
Special Populations
Pregnancy
- Rifampin, isoniazid, ethambutol, and pyrazinamide are safe; streptomycin is contraindicated due to fetal ototoxicity. 3
- BPaLM and BPaL are contraindicated in pregnancy (pretomanid reproductive toxicity unknown). 6, 3, 1
- Do NOT use ethionamide in pregnancy; substitute with a linezolid-based variation of the 9-month regimen. 6, 1
Children
- Adult regimens are used with weight-adjusted dosing; ethambutol is generally avoided in children <6 years because visual monitoring is difficult—streptomycin is the alternative. 3
- Do NOT give BPaLM to children <14 years (pretomanid not studied); opt for the 9-month regimen instead. 6, 1
HIV Co-Infection
- Minimum 9 months of anti-TB therapy for HIV-infected patients with disseminated disease, continuing for at least 6 months after documented sputum culture conversion. 3
- If DST results are unavailable, maintain ethambutol (or streptomycin) for the entire 9-month course to mitigate rapid progression risk. 3
Critical Pitfalls to Avoid
- Do NOT use fewer than four effective drugs in the intensive phase of long regimens—this predisposes to treatment failure. 6, 1
- Do NOT discontinue therapy early after culture conversion; complete the full prescribed duration (6,9, or 18–20 months). 6, 1
- Do NOT modify standardized regimens (BPaLM, BPaL, 9-month) by adding or removing drugs—this increases failure and resistance amplification risk. 6, 1
- Do NOT extend BPaLM beyond 6 months; if response is inadequate, switch to an individualized 18–20-month regimen rather than prolonging BPaLM. 6, 1
- Do NOT reuse the same regimen after recurrence or failure—this promotes further resistance. 3
- Do NOT omit lumbar puncture in miliary TB—missing CNS disease leads to inadequate 6–9-month therapy when 12 months is required. 3
- Do NOT delay BPaLM initiation awaiting fluoroquinolone DST—start empirically and adjust to BPaL if resistance is confirmed. 1
Programmatic Challenges in NTEP Implementation
- Only 69% of microbiologically confirmed TB patients undergo drug-sensitivity testing, and only 16% of staff are trained in recent guidelines. 7
- No separate district DR-TB treatment centers with airborne infection control facilities exist in many areas, and only 30% of DR-TB patients receive psychological assessment. 7
- Prioritizing establishment of district DR-TB treatment centers, posting dedicated clinical psychologists, and training all staff on DR-TB management guidelines will significantly improve program outcomes. 7